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Abstract Sleep problems in children with autism spectrum
disorders (ASD) are under-recognized and under-treated.
Identifying treatment value accounting for health effects on
family members (spillovers) could improve the perceived
cost-effectiveness of interventions to improve child sleep
habits. A prospective cohort study (N = 224) was conducted
with registry and postal survey data completed by the primary
caregiver.We calculated quality of life outcomes for the child
and the primary caregiver associated with treatments to
improve sleep in the child based on prior clinical trials. Pre-
dicted treatment effects for melatonin and behavioral
interventions were similar in magnitude for the child and for
the caregiver. Accounting for caregiver spillover effects
associated with treatments for the child with ASD increases
treatment benefits and improves cost-effectiveness profiles.
Keywords Autism spectrum disorder  Child health 
Caregiver health  Child sleep habits  Quality adjusted life
year  Cost-effectiveness analysis
Introduction
Economic evaluation complements comparative effective-
ness research by assisting in decision making about whether
technologies for the treatment or prevention of disease
provide good value. Technologies that benefit patients and
prove to be cost-effective provide a signal to decision-
makers that the technology warrants translation into prac-
tice. Given concerns over the slow uptake of effective
technologies by health care systems, some have viewed
information from an economic evaluation as a useful tool
that can speed up the pace in which interventions are
translated or implemented into practice (Glasgow and
Emmons 2007; Glasgow and Steiner 2012). Indeed, eco-
nomic evaluations provide one of the ‘‘greatest opportuni-
ties’’ to rapidly translate clinical comparative effectiveness
evidence into practice or policy as it provides a clear ratio-
nale for decision-makers to act (Glasgow et al. 2013).
The US panel on Cost-Effectiveness in Health and
Medicine recommended the use of a societal perspective in
economic evaluations (Gold et al. 1996). The societal
perspective takes into account all health care costs and
benefits created by the intervention irrespective of where
they occur in society. Recently, the perspective of
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economic evaluations has broadened to include family
effects in the calculation of cost-effectiveness ratios (Basu
and Meltzer 2005; Basu et al. 2010; Prosser et al. 2015).
Under this perspective, it is recognized that health and
medical interventions for patients can have substantial
spillover effects on family members in terms of quality
adjusted life years (QALYs) gained or lost. The QALY is a
standard metric that is recommended for cost-effectiveness
analysis by the National Institute for Health and Clinical
Excellence (NICE) (2013) and the US Panel on Cost-
Effectiveness in Health and Medicine (Weinstein et al.
1996). It combines the value of health-related quality of
life or preference-based health utility and life years gained
into a single metric. Failure to account for family spillover
effects can bias cost-effectiveness ratios used to inform
payers and other decision makers. Effective interventions
evaluated solely from the patient perspective can have
unfavorable cost-effectiveness ratios that exceed typical
threshold values, such as the $100,000 per QALY mark,
but lie within these thresholds if the intervention confers
additional health benefits on the family and these benefits
can be accurately measured and incorporated into the
economic evaluation.
The potential for health interventions to have spillover
effects on the family may be especially pronounced for
child health services (Brouwer et al. 2009; Meltzer and
Smith 2012). In 1996, the US Panel on Cost-Effectiveness
in Health and Medicine included an evaluation of folic acid
fortification strategies to illustrate applications involving
children. The authors recognized the potential for inter-
ventions that prevent spina bifida or other neural tube
defects to have health benefits for the family (Kelly et al.
1996). However, the authors (and the panel) recommended
against including these benefits in a Reference Case cost-
effectiveness analysis (CEA) because methods for incor-
porating family spillover effects were in the early stages of
development and data on such spillover effects were not
available. Including family spillover effects in the CEA
would have increased the QALYs gained for all of the food
fortification interventions under study.
Unlike the current guidance in the US, the UK explicitly
recommends the inclusion of family spillover effects in a
Reference Case CEA. A number of papers have now
addressed methods for incorporating spillover effects in
economic evaluations (Basu and Meltzer 2005; Basu et al.
2010), yet application of these methods in the literature
remain limited (Wittenberg and Prosser 2013). Thus, the
purpose of this paper is to provide estimates of the potential
QALYs gained by children with autism spectrum disorders
(ASD) from treatments for sleep problems, as well as the
spillover effects of sleep treatments on their primary
caregiver. We hypothesized that sleep treatments have the
potential to improve quality of life outcomes as measured
by QALYs for both the child with an ASD and their
caregiver. Because QALYs can be measured on the same
scale, an analysis of gains to children can be directly
compared with gains to caregivers to determine their rel-
ative importance to overall health gains and potential
impact on estimated cost-effectiveness ratios.
Background on Children with ASD
ASD is a complex neurodevelopmental condition that is
defined by impairments in social interaction, communica-
tion, and repetitive and stereotyped behaviors and interests
(American Psychiatric Association 2000). While individ-
uals with ASD are characterized by a core set of symptoms,
there is wide heterogeneity in the severity of the disorder
and there are many co-occurring medical conditions that
complicate diagnosis, management, and outcome. Children
with ASD may have associated problems with aberrant
behavior including severe tantrums, noncompliance,
destructiveness, and self-injury, as well as psychiatric
comorbidities such as anxiety and attention deficit disorder
(Arnold et al. 2003; Simonoff et al. 2008). Other common
co-occurring conditions include cognitive deficits, epi-
lepsy, gastrointestinal problems, and sleep problems (Levy
et al. 2010; Coury et al. 2012; Reynolds and Malow 2011).
Sleep problems are especially problematic, as they may
exacerbate the core and related symptoms of ASD (Malow
et al. 2012a). Parental reported prevalence of sleep problems
in children with ASD range from 44 to 83 % (Krakowiak
et al. 2008). Sleep problems have been associated with
worsening of problematic daytime behaviors including social
skills deficits, attention deficit hyperactivity disorder, and
repetitive behaviors (Goldman et al. 2011). Sleep problems
in children with ASD are known to affect family functioning
that may be related to concomitant parental sleep problems
(Malow et al. 2014). Evidence suggests that sleep problems
in this population may be under recognized and under treated
because of the emphasis on the daytime behavioral issues
(Reynolds and Malow 2011). Effective interventions for
sleep problems have the potential to improve health out-
comes for children with ASD and their families if they are
widely adopted within health care systems.
Treatments for sleep problems in children with ASD are
limited. Evidence supports the use of behavioral interven-
tions in childrenwithASDwho have sleep problems (Cortesi
et al. 2012; Reed et al. 2009; Malow et al. 2012a, 2014)
particularly training parents to develop appropriate bedtime
hygiene for their affected children. Complementary and
alternative medicine such as massage therapy, aromather-
apy, and weighted blankets as well as medications such as
risperidone and mirtazapine do not have sufficient evidence
to support their use in children with ASD (Malow et al.
2012b). Melatonin, which has sleep-promoting and
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chronobiotic properties, is an approved US Food and Drug
Administration nutrition supplement that showed promising
results in small, randomized controlled trials as a
monotherapy or combination with parent-based sleep edu-
cation (Rossignol and Frye 2011; Cortesi et al. 2012; Malow
et al. 2012a). It is relatively safe andwell-tolerated in treating
sleep problems among children with ASD. In addition,
melatonin is an example of a treatment that not only
improves sleep, but also results in improvements in behavior
and parenting stress (Malow et al. 2012a).
This study quantifies gains in QALYs for children with
ASD and their caregivers from interventions to improve
sleep in the child. The gain in QALYs for the caregiver
represents the potential spillover effects from treatment of
the child with ASD and sleep problems. Our goal is to
improve the evidence base for assessing the value of sleep
interventions in this population in order to increase their
adoption within health systems when warranted.
Methods
Participants and Study Design
The study used a cross-sectional and prospective design with
two sources of data: outcome measures of interest were
obtained from a postal survey and combined with clinical
data from treatment centers. Participants for the study were
recruited through a registry maintained by the Autism
Treatment Network (ATN) funded by Autism Speaks. Two
sites of the ATN were used for this study: a developmental
center in Little Rock, Arkansas, and an outpatient psychi-
atric clinic at Columbia University Medical Center in New
York, New York. All children had a clinical diagnosis of an
ASD meeting DSM-IV-TR criteria (e.g., Autistic Disorder,
PDD-NOS, or Asperger’s Disorder). The sample included
families of children with an ASD that agreed to participate in
future research studies as part of the ATN. English-speaking
families of children with an ASD who were between 4 and
17 years of age were contacted by mail to see if they would
be interested in participating in the study. Details on the
sampling procedure are reported elsewhere (Payakachat
et al. 2014). The institutional review boards at Columbia
University and the University of Arkansas for Medical
Sciences approved the study.
Patient-reported Outcome Measures
Preference-based HRQoL Instruments
Two generic preference-based HRQoL instruments were
selected for both caregivers and children because infor-
mation on which instrument would be most sensitive to
changes in sleep problems was not available. In this study,
we compared estimates from the HUI-3 (Health Utilities
Index Mark 3) (Feeny et al. 2002) and the QWB-SA
(Quality Well-being Self-Administered) (Kaplan and
Anderson 1996) in children. The HUI-3 has eight
domains—vision, hearing, speech, ambulation, dexterity,
emotion, cognition, and pain—each with five or six
response levels. This creates a total of 972,000 possible
combinations of unique health states that are linked to pre-
determined preference-weighted scores. The HUI-3 index
ranges from -0.36 (some health states are considered
worse than dead) to 1 (perfect health state). The HUI-3 was
selected because of its psychometric properties (Horsman
et al. 2003) and it has been used in many studies involving
children including those with autism (Petrou and Kupek
2009; Tilford et al. 2012). The QWB-SA is a self-admin-
istered instrument combining three scales of functioning
(mobility, physical activity, and social activity including
completion of role expectation) with a measure of symp-
toms and problems to produce a point-in-time expression
of well-being that ranges from 0 (death) to 1 (symptomatic
full function). It was selected because it has been found to
be a sensitive measure for mental health conditions (Pyne
et al. 2003)and has been used in children (Smith-Olinde
et al. 2008), albeit less frequently. The primary caregivers
completed both instruments for their children. For care-
givers, the SF-6D (Brazier and Roberts 2004)and EQ-5D
(Johnson et al. 1998) were selected as they have been
compared frequently in the literature.
Sleep Problems
The CSHQ (Children’s Sleep Habits Questionnaire) was
used to assess sleep behaviors and problems in children
(parent-reported instrument) (Owens et al. 2000). The
original 45-item CSHQ was revised to eliminate redundant
or ambiguous items and left with 35 items that can be
grouped into eight sleep domains (bedtime resistance, sleep
onset delay, sleep duration, sleep anxiety, night wakings,
parasomnias, sleep disordered breathing, and daytime
sleepiness). A total score was calculated by summing all
items of the eight domains, but it consisted of only 33 items
because two items on the bedtime resistance and sleep
anxiety domains were identical. A higher total score indi-
cates more disturbed sleep. The CSHQ has good psycho-
metric properties and has been used to study sleep problems
in children with ASD (Krakowiak et al. 2008; Cortesi et al.
2012). A recent practice guideline recommends using the
CSHQ to assess children for sleep problems (Malow et al.
2012b). For the purpose of this study, a cut-off point of 41
was used to identify children with clinically significant sleep
disturbance, based on work done in children with typical
development (Owens et al. 2000). The CSHQ was used as
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the main outcome measure in several recent clinical trials
(Cortesi et al. 2012; Malow et al. 2012a, 2014).
Other Patient-reported Measures
A number of other measures were collected to further
assess caregiver quality of life and the severity of the
child’s condition. The CES-D (Center for Epidemiologic
Studies Depression Scale) was used to assess depression
symptoms in caregivers. It has 20 items with scores ranging
from 0 to 60 with higher scores reflecting more depressive
symptoms (Radloff 1977). A cut-off point of 16 on the
CES-D was used to indicate high level of depressive
symptoms. Caregiver burden and well-being was measured
using the CarerQol instrument that is comprised of the
CarerQol visual analogue scale (CarerQol-VAS) and its
descriptive system (CarerQol-7D) (Brouwer et al. 2006). A
weighted sum score of the CarerQol-7D ranges from 0
(worst care-related quality of life) to 100 (best care-related
quality of life) (Hoefman et al. 2014). The CarerQol-VAS
measures well-being of parents in terms of happiness from
0 (completely unhappy) to 10 (completely happy).
Clinical Measures
The ADOS severity score (range of 1–10) is a calibrated
metric that is used to quantify the relative severity of ASD
symptoms (Shumway et al. 2012). A higher score represents
more severe ASD symptoms. Cognitive ability was mea-
sured within the ATN by the Stanford-Binet Intelligence
Scales, 5th edition (SB-5), Abbreviated Battery, an indi-
vidually administered, standardized cognitive assessment
that could be used with individuals aged 2 years and older. If
the child could not be evaluated on the SB-5, the Mullen
Scales of Early Learning, American Guidance Service
Edition (Mullen 1997) or the Bayley Scales of Infant
Development, 3rd edition (Bayley 2006) were used to assess
cognitive functioning. All three cognitive ability measures
are in comparison to age-based norms and provide a stan-
dard score with a mean of 100 and standard deviation of 15.
Statistical Analysis
Demographic information and instrument scores for chil-
dren with ASD and their caregivers were provided as
descriptive statistics. Spearman’s rank correlation was
employed to explore associations between the CSHQ total
score from children with ASD and other instrument scores.
We further determined the associations between the CSHQ
total scores and health utility scores using ordinary least
squares (OLS) regression, controlling for child age,
severity of the condition (measured by the ADOS), cog-
nitive ability, and child gender.
Because health utility scores typically have non-normal
distributions with negative skew and ceiling effects (a large
spike at the upper bound of perfect health), various sta-
tistical modeling approaches have been considered
including beta regression and two-part models (Brazier
et al. 2010). Recent simulation studies found that OLS can
produce unbiased estimates under specific circumstances
(Pullenayegum et al. 2010). When these circumstances are
not met, especially the presence of a large spike at 1 in the
health utility score distribution, two-part models and beta
regression approaches have been shown to improve model
fit over OLS (Basu and Manca 2012).
The distribution of HUI3 and QWB-SA scores in our
sample was skewed (skewness of -0.9 and 0.4), but only a
small percentage of respondent HUI3 scores (4.1 %) and
QWB-SA scores (3.5 %) reached the ceiling of 1. Thus, the
distributions of health utility scores for children with ASD
do not correspond to the distribution patterns that benefit
from beta regression or other estimation approaches (Basu
and Manca 2012). For this reason, we decided to use OLS
for analyses involving child outcomes in this study. For
caregiver analyses, we compared estimates from the beta
quasi-likelihood approach and OLS because of the large
ceiling effects (30.4 %) and skew (-1.2) in the distribution
of the EQ-5D. Only one caregiver reported perfect health
on the SF6D and skew was minimal (-0.10). Parameter
estimates differed by less than 5 % between the alternative
estimators, so we reported OLS estimates in all analyses.
Model specification was investigated using the Ramsey
RESET test (1969) and the Link test (Pregibon 1980).
QALY estimates were generated from two randomized
controlled trials that used the CSHQ as a primary outcome
measure (Cortesi et al. 2012; Malow et al. 2014). The trials
provided estimates in terms of reduced CSHQ scores
among children with ASD for four different interventions
including melatonin, cognitive behavioral therapy (CBT),
combination of melatonin and CBT, and a parent-based
sleep intervention. Changes in CSHQ total scores were
used to predict one-year QALY gains for both the child and
the primary caregiver using the estimated relationships
described above. Bootstrapping standard errors and bias-
corrected 95 % confidence intervals for all OLS estimates
are calculated with 1000 replications. SAS 9.3 (SAS
Institute, Cary, NC) and Stata/SE 13.0 (StataCorp, College
Station, TX) were utilized for all analyses.
Results
A total of 224 children with ASD and their caregivers
participated in this study (response rate of 59.2 %). Aver-
age ages of children and caregivers were 8.2 (SD = 3.5)
and 39.4 (SD = 8.3) years old, respectively. The majority
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of the children were male (86.6 %) while the caregivers
were mostly female (89.5 %) with 94.5 % of them being
the biological parents of the affected children. One third of
the caregivers (34.8 %) reported annual household income
greater than $100,000. The demographic characteristics of
study participants are provided in Table 1.
Table 2 provides summary outcome measures and cor-
relations with sleep for children with ASD and their care-
givers. HUI-3 and QWB-SA scores for children with ASD
were 0.659 (SD = 0.234) and 0.591 (SD = 0.164) on a
scale with 1.0 representing perfect health and 0 repre-
senting dead. Both instrument scores were significantly
correlated with the CSHQ total scores. Summary statistics
from the CSHQ indicated significant sleep problems in this
sample with an average score of 49.1 (SD = 8.3) and
83.1 % reporting total scores[41. As hypothesized, CSHQ
total scores were significantly and negatively correlated
with caregiver sleep hours.
Preference-based HRQoL scores for the caregiver EQ-
5D and SF-6D were 0.847 (SD = 0.138) and 0.741
(SD = 0.119) reflecting the differences in scale for the two
instruments. Both instruments were significantly correlated
with the CSHQ and the number of hours of sleep reported
by the caregiver. Other measures of health had the
hypothesized relationship to the CSHQ and caregiver sleep
hours. The CES-D averaged 13.8 (SD = 10.6) with 39.3 %
reaching the threshold (CESD scores C16) for depressive
symptoms. Both the CarerQol-7D and CarerQol-VAS
indicated negative care-related quality of life and well-
being effects on the caregiver associated with sleep prob-
lems in the child.
Table 3 provides summary outcome scores for both the
child and caregiver by hours of sleep as reported by the
primary caregiver. Reported hours of sleep were catego-
rized by B5 h of sleep, 6 h of sleep, 7 h of sleep, and C8 h
of sleep per night. Approximately 25 % of caregivers
reported sleeping B5 h per night and more than half
reported sleeping 6 h or less. In general, child and care-
giver outcomes followed a step function in relation to
reported hours of sleep with all tests for trend significant at
the p value of 0.01 with the exception of the HUI-3 score
(p = 0.052). CSHQ scores were highest (52.9; 95 % CI
Table 1 Demographic
characteristics of children with
ASDs and their caregivers
(n = 224)
Children with ASDsa Caregiversb
Age, mean ± SD (range) 8.2 ± 3.5 (4.0–17.9) 39.4 ± 8.3 (21.6–61.0)
Gender
Male 86.6 % 10.5 %
Female 13.4 % 89.5 %
Race/ethnicity
Caucasian 75.2 % 72.8 %
African American 9.2 % 9.4 %
Hispanic 9.2 % 10.8 %
Asian 2.3 % 3.3 %
Other 4.1 % 3.3 %
Relationship to the child
Biological parent 94.9 %
Divorced 10.0 %
Education
High school or lower 8.5 %
Some college or higher 91.5 %
Income
\$20,000 14.2 %
$20,000–$35,000 12.7 %
$35,000–$60,000 15.7 %
$60,000–$100,00 22.5 %
[$100,000 34.8 %
Employment status
Part-time or full-time 61.7 %
Not employed 38.3 %
SD standard deviation
a 0–2 % missing
b 2–5 % missing
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Table 2 Descriptive statistics and correlations between health measures, CSHQ scores, and caregiver sleep hours
N Mean ± SD (range) Spearman correlations
with CSHQ summary scores
Spearman correlations
with caregiver sleep hours
Child
HUI-3 score 218 0.659 ± 0.234
(-0.098–1.0)
-0.177* 0.123
QWB-SA score 224 0.591 ± 0.164
(0.182–1.0)
-0.228* 0.179*
CSHQ summary score 202 49.1 ± 8.4
(35–84)
1.000 -0.270**
CSHQ score[ 41b 163 83.1 %
Caregiver
EQ-5D score 219 0.847 ± 0.139
(0.308–1.0)
-0.227* 0.305**
SF-6D score 213 0.741 ± 0.119
(0.378–1.0)
-0.285** 0.261*
CES-D 203 13.8 ± 10.6
(0–55)
-0.256** -0.345**
CES-D C 16a 84 39.3 %
CarerQol-7D 215 75.0 ± 19.7
(15.3–100)
-0.244** -0.344**
CarerQol-VAS (Happiness scale) 215 7.4 ± 1.9
(0–10)
-0.216* 0.299**
SD standard deviation, CSHQ Children’s Sleep Habits Questionnaire, HUI-3 Health Utilities Index Mark 3, QWB-SA Quality of Well-Being Self-
Administered, EQ-5D 5-Dimension EuroQol, SF-6D 6-Dimension Short-Form, CES-D Center for Epidemiologic Studies Depression Scale,
CarerQol-7D 7-Dimension Care-related Quality of Life, CarerQol-VAS Care-related Quality of life Visual Analog Scale
a CES-D score C16 indicates clinical depressive symptoms
b CSHQ summary score[41 indicates significant sleep problems
Table 3 Health outcomes of children with ASDs and caregivers by self-reported number of caregiver sleep hours
Sleep
hours
N
(%)
Child outcomes (LSMEAN, 95 % CL) Caregiver outcomes (LSMEAN, 95 % CL)
CSHQ
Score
HUI3
Score
QWB-SA
Score
SF-6D
Score
EQ-5D
Score
CES-D
Score
CarerQol
7D
CarerQolVAS
B5 h 55
(24.9 %)
52.2
(48.9–55.3)
0.580
(0.494–0.677)
0.533
(0.476–0.598)
0.710
(0.670–0.756)
0.785
(0.743–0.839)
18.0
(14.0–22.0)
62.6
(55.6–69.6)
6.6
(5.9–7.3)
6 h 57
(25.8 %)
48.4
(45.0–51.5)
0.640
(0.555–0.739)
0.533
(0.475–0.600)
0.738
(0.698–0.786)
0.847
(0.803–0.903)
14.0
(9.9–18.0)
72.4*
(65.3–79.6)
7.4
(6.8–8.2)
7 h 75
(33.9 %)
47.8*
(44.8–50.5)
0.628
(0.555–0.717)
0.570
(0.520–0.631)
0.783**
(0.748–0.826)
0.888**
(0.851–0.940)
8.8**
(5.2–12.4)
78.8**
(72.4–85.1)
7.9**
(7.4–8.7)
C8 h 34
(15.4 %)
44.6**
(40.6–48.4)
0.685
(0.578–0.798)
0.619
(0.546–0.698)
0.795**
(0.744–0.852)
0.923**
(0.866–0.987)
7.8**
(3.0–12.5)
80.2**
(71.5–89.0)
8.1**
(7.3–9.0)
LSMEAN = Least squared mean, controlling for parent age, parent gender, child age, child gender and their 95 % confidence limits
SD standard deviation, CSHQ Children’s Sleep Habits Questionnaire, HUI-3 Health Utilities Index Mark 3, QWB-SA Quality of Well-Being Self-
Administered, EQ-5D 5-Dimension EuroQol, SF-6D 6-Dimension Short-Form, CES-D Center for Epidemiologic Studies Depression Scale,
CarerQol-7D 7-Dimension Care-related Quality of Life, CarerQol-VAS Care-related Quality of life Visual Analog Scale
* p\ 0.05, compared to parents who reported number of sleep at night B5 h
** p\ 0.001, compared to parents who reported number of sleep at night B5 h
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48.9–55.3) for caregivers who reported sleeping the least
after adjusting for age and gender and were significantly
lower for caregivers who reported more sleep.
Consistent with our main hypothesis, lower health utility
scores for the child and poorer health status for the primary
caregiver were associated with child sleep problems.
Caregivers who reported that they slept B5 h per night had
significantly lower SF-6D and EQ-5D scores and Car-
erQol-VAS scores than caregivers who slept 7 and C8 h
per night. We also found that caregivers who reported that
they slept B5 h per night had significantly higher CES-D
and lower CarerQol-7D scores suggesting the presence of
more depressive symptoms and worse quality of life.
Indeed, 58.3 % of caregivers met the threshold for clini-
cally depressive symptoms if they slept B5 h per night and
48.1 % met the threshold if they slept 6 h per night. This
percentage fell to 26.5 and 27.3 % if caregivers slept 7 or
8 h or more per night.
Table 4 provides OLS regression coefficients for rela-
tionships between the CSHQ total scores and the health
utility scores for the child and caregiver after controlling
for age, gender, cognitive ability, and the severity of the
ASD. Estimates are presented as one-unit changes in the
CSHQ effect on the utility scores for the different instru-
ments. To put the estimates into perspective, a standard
deviation decrease in the CSHQ total score of 8.4 points
(indicating better sleep habits) leads to a clinically signif-
icant increase in the child’s HUI-3 score by 0.036 points.
The same change in the CSHQ also generates an increase
in the caregiver’s SF-6D score of 0.035 points, suggesting a
potential gain in QALYs that doubles when effects on the
caregivers are included.
Table 5 summarizes CSHQ total scores at baseline and
following treatment in two randomized trials that examined
the effect of melatonin, cognitive behavioral therapy
(CBT), combination of melatonin and CBT, and parent-
based sleep education. Associated QALY gains for the
child and the caregiver are presented based on differences
in CSHQ total scores from the treatment. The trial by
Cortesi et al. (2012) found large improvements in CSHQ
total scores from treatment with melatonin (-11.9) and the
combination of melatonin and CBT (-18.3) that translate
into large QALY gains for both the child and the caregiver.
For melatonin, one-year QALY gains equaled 0.049 (95 %
CI 0.047–0.51) for the child and 0.050 (95 % CI
0.035–0.064) for the caregiver. Melatonin and CBT
Table 4 Estimated effect of CSHQ total scores on child and caregiver utility measures
Measure CSHQ beta Bootstrap
standard errorc
Bias-corrected
95 % confidence interval
Adjusted R2 Link test
(p value)
Ramsey reset test
(p value)
Childa
HUI3 -0.0043* 0.0019 -0.0081, -0.0005 0.168 0.182 0.396
QWB-SA -0.0045** 0.0013 -0.0071, -0.0021 0.076 0.398 0.400
Caregiverb
SF6D -0.0042** 0.0011 -0.0064, -0.0021 0.073 0.334 0.113
EQ5D -0.0038* 0.0015 -0.0069, -0.0010 0.077 0.910 0.090
a OLS regression controlling for ADOS, log(IQ), child age, child gender
b OLS regression controlling for ADOS, log(IQ), caregiver age and gender
c Bootstrapping standard error with 1000 replications
* p\ 0.05
** p\ 0.001
Table 5 Estimated child and spillover QALYs gained from alternative treatments for sleep problems in children with ASD
Treatment Baseline
CSHQ
Treatment
CSHQ
Mean difference
(pooled SD)
Child
QALYs gaineda
Mean (95 % CI)
Caregiver spillover
QALYs gaineda
Mean (95 % CI)
Melatonin (Malow et al. 2014) 66.7 (8.6) 54.8 (6.2) -11.9 (7.48) 0.049 (0.047–0.051) 0.050 (0.035–0.064)
CBT (Malow et al. 2014) 64.5 (5.5) 60.1 (4.7) -4.4 (5.11) 0.017 (0.017–0.019) 0.019 (0.018–0.020)
Melatonin and CBT (Malow et al. 2014) 66.1 (5.5) 47.8 (2.9) -18.3 (4.39) 0.076 (0.072–0.080) 0.078 (0.075–0.080)
Parent-based sleep education (Cortesi
et al. 2012)
55.8 (8.1) 49.3 (8.2) -6.2 (8.0) 0.025 (0.023–0.026) 0.026 (0.025–0.028)
a Estimates assume 1-year treatment gain for comparability using bootstrap with 1000 replications with 95 % bias-corrected confidence interval;
based on author calculations from information in table
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generated QALY gains of 0.076 (95 % CI 0.072–0.080) for
the child and 0.078 (95 % CI 0.075–0.080) for the care-
giver. Interestingly, the incremental improvement in CSHQ
scores from the combination of CBT and melatonin over
melatonin alone (-6.4) is similar to the improvement in
CSHQ total scores reported by Malow et al. (2014) (-6.5)
where 15 % of children were on melatonin and others
could have initiated melatonin prior to enrollment in the
trial.
Discussion
The goal of this study was to quantify the importance of
sleep problems on the health of children with ASD and
their primary caregiver using the QALY metric to enable
identification of potential spillover effects on the caregiver
from successful treatment of the child. Evidence on the
effectiveness of treatment for sleep problems in children
with ASD has been established in prior studies using the
CSHQ as a primary outcome measure (Cortesi et al. 2012;
Malow et al. 2014). Both treatment with melatonin and
behavioral interventions can improve the sleep habits and
the health of the child with ASD. The evidence also indi-
cates that effective treatment for the child can improve
health outcomes for caregivers (Malow et al. 2012a).
However, evidence on the potential cost-effectiveness of
treatment, especially behavioral treatments for sleep
problems in children with ASD, is lacking. Without such
evidence, effective treatments may not become part of
routine practice or may require much more time for such
treatments to become routine practice. Thus, this study
provides new information on the potential QALYs gained
to the child with ASD from treatment of sleep problems
and the spillover QALYs to the caregiver that can be used
in cost-effectiveness evaluations to aid decision-making.
Our findings have substantial implications for cost-ef-
fectiveness evaluations of sleep treatment for children with
ASD and other populations as well. We estimate that the
spillover QALYs gained by the caregiver are of similar
magnitude as the gains to the child. Cost-effectiveness
evaluations from the patient perspective that ignore these
spillover benefits will therefore greatly understate the
benefits of treatment and worsen the estimated cost-effec-
tiveness ratio. Indeed, in the context of treatment for sleep
problems in children with ASD, the spillover effect is large
with QALY gains approximately double from gains based
solely on the child and calls into question cost-effective-
ness analysis conducted from the perspective of the patient
in this population of children and other similar contexts.
The US panel on Cost-Effectiveness in Health and
Medicine acknowledged the potential for spillover effects
to influence estimated cost-effectiveness ratios, but
recommended against their inclusion in a reference case
analysis because data and methods for incorporating such
effects were lacking (Kelly et al. 1996). The last decade has
witnessed substantial progress in methods for incorporating
caregiver and family effects in economic evaluations
(Tilford and Payakachat 2014). Basu and Meltzer (2005)
and Basu et al. (2010) provided necessary theoretical
guidance to focus the discussion of family effects and
economic evaluation, but data from applications to specific
conditions and treatments remain limited. In attempting to
demonstrate the real value of health interventions, and
given the development in knowledge and methods, the aim
of economic evaluation should be to include family effects
whenever relevant. Wittenberg and Prosser (2013) recently
published a systematic review of studies that specifically
examined spillover effects or permitted calculation of such
effects and found seven studies that directly estimated
effects and eight studies where effects could be inferred. In
general, the findings showed a range of effects from non-
existent to large with estimates varying in relation to
condition, age group, and methodology.
Because this study includes clinical measures in relation
to health utility measures, we can estimate potential spil-
lover effects of treatment for sleep problems in children
with ASD. The cost-effectiveness findings are unequivocal
for treatment with melatonin; it is a low cost, safe, and
efficacious supplement. However, the incremental cost-ef-
fectiveness of behavioral therapy to improve sleep over
melatonin alone requires formal evaluation, as it likely is
more expensive in both time and resources. Our findings
suggest that a cost-effectiveness evaluation at the patient
level would generate approximately 0.03 QALYs per year
for the child (assuming the intervention has benefits that
extend beyond the duration of the trial). While this gain in
QALYs meets the definition of clinically important, such
an evaluation would greatly understate the true benefits by
ignoring the health benefits to the caregiver. The findings
suggest an additional gain in caregiver spillover QALYs of
a similar magnitude (approximately 0.03 QALYs). Hence,
a family perspective produces cost-effectiveness ratios
approximately half as large of those from a patient per-
spective. Cost-effectiveness evidence for behavioral inter-
ventions associated with sleep problems may indicate good
value, but suggest otherwise if family effects are ignored.
Beyond the findings related to spillover QALYs, this
study illustrates the need for greater understanding of sleep
problems in children with ASD and the health effects on
caregivers. In this sample of medically diagnosed children,
we found that 88 % met the threshold for sleep problems
based on the CSHQ, which was on the high end of prior
estimates for this population (Krakowiak et al. 2008).
Population-based studies typically find that 23 % of typi-
cally developed children will meet this threshold (Owens
3620 J Autism Dev Disord (2015) 45:3613–3623
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et al. 2000). The cutoff point for sleep problems among
children with ASD may be different. In addition, we found
that approximately 25 % of caregivers in this study report
sleeping 5 or fewer hours per night with 60 % of them
reporting CES-D scores above the threshold for identifying
individuals at risk for clinical depression. Data from the
2013 American Time Use Survey indicate that approxi-
mately 3.5 % of parents sleep five or fewer hours a day
(Bureau of Labor Statistics 2014). Our findings contribute
to prior research on maternal quality of life and risk for
depression that sought to identify which mothers of chil-
dren with ASD are at most risk for depression (Zablotsky
et al. 2013). Our results are not intended to suggest a causal
relationship between sleep and depression, as we recognize
the limitations of cross-sectional data and the potential for
relationships to be recursive as described by Zablotsky
et al. (2013). Still, sleep problems in this population and
the associated implications for caregivers with respect to
their own sleep habits and health deserve broader recog-
nition and intervention where warranted.
Estimates of caregiver spillover effects associated with
child sleep problems were based on generic instruments for
measuring health utility. Generic instruments may not be
sufficiently sensitive to capture health-related quality of
life effects in caregivers and other family members. For
this reason, we chose to compare findings from two
instruments, as there was no guidance in the literature.
Estimates of potential QALYs gained by caregivers from
sleep treatments for the child were similar irrespective of
whether the EQ-5D or the SF-6D was used to measure
spillover effects. Interestingly, one study evaluated whe-
ther adding a domain for sleep would improve the sensi-
tivity of the EQ-5D because of the recognition of the
importance of sleep to health (Yang et al. 2014). The
findings did not indicate any improvement over the original
instrument.
The major limitation of the current study is the cross-
sectional design used to estimate potential QALYs gained.
Prior research established the efficacy of treatment for
sleep problems; our study provides models to quantify the
QALYs gained from these treatments. Since our estimated
relationships are robust to instrument selection and mod-
eling approach, we have confidence that our QALY esti-
mates for the child and the caregiver qualify as necessary
data that can be used in cost-effectiveness applications.
Direct collection of evidence in the context of an ongoing
intervention remains a priority, especially in relation to
specific interventions for targeted sleep problems (night
wakings versus sleep onset delay for example).
Another limitation is that we use caregiver responses to
measure the health-related quality of life of the child as
well as self-reported sleep problems and sleep hours. Direct
measures of sleep duration such as autography would have
strengthened the study (Lichstein et al. 2006). Issues in
conducting economic evaluation in children have been
recognized (Ungar and Gerber 2010) and new methods and
instruments are being developed in response to these
challenges (Prosser et al. 2007). Given the symptoms
associated with ASD, few alternatives to caregiver report
of health related quality of life exist (Payakachat et al.
2012) and most studies of children with neurodevelopment
disorders rely on this methodology to generate estimates of
cost-effectiveness. Our prior research has established that
caregiver reported HUI-3 scores in particular are strongly
correlated with other outcome measures used in ASD
research (Tilford et al. 2012).
The potential importance and implications of family
spillover effects for cost-effectiveness evaluations are now
recognized and warrant serious discussion in decisions
regarding the allocation of health resources. Incorporating
spillover effects in cost-effectiveness evaluations has the
potential to greatly alter estimated cost-effectiveness ratios
of interventions and hence, change decisions regarding
their use and implementation. While incorporation of
family effects may make the actual conduct of cost-effec-
tiveness analysis more difficult, the results presented here
suggest it can drastically improve the accuracy of estimated
health effects from interventions. Incorporating family
effects may be better aligned with constituent understand-
ing of ASD, leading to more useful application and
appreciation for cost-effectiveness evaluation of services to
treat children affected with the condition (Tilford and
Payakachat 2014).
Health research based on QALYs provide an important
metric to identify value especially as it allows for incor-
porating family spillover effects to ensure that the full
value of health resources are included in decision-making.
Widespread implementation of interventions for managing
sleep problems in children with ASD has the potential to
improve their health and well-being as well as their care-
givers. In addition, better health of caregivers may benefit a
broader society as they could maintain their productivity,
better job performance, and potentially decrease health
care cost (Swanson et al. 2011). Our study confirms that
decisions on whether to implement behavioral treatments
for sleep problems in children with ASD or other condi-
tions with a similar context, should incorporate family
spillover effects to identify their full value.
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